In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leela Barham

Latest From Leela Barham

Economic Crisis Expected To Shape UK’s Future Drug Pricing Deal

The pharmaceutical industry has warned the UK’s new government about the impact of unprecedented industry payments on medicines supply in the short term and their potential to reduce inward investment in the long term. Along with economic pressures, these considerations will be among the factors forming the backdrop to negotiations on a deal that will determine pricing and access for branded medicines access from 2024 onwards.

Europe United Kingdom

Pharma Firms Keep A Close Eye On NICE's New HTA Approach In UK

Companies are keen to know how the disease severity modifier and a more flexible approach to uncertainty will be applied to health technology appraisals for drugs in practice. They also want reassurance that there will be consistency in deliberations by NICE’s various committees and advisory groups.

Europe United Kingdom

Industry Laments UK Decision To Go Ahead With ‘Unprecedented’ Sales Repayments

The UK government has confirmed plans to raise payments made by drug companies in the statutory scheme for branded medicines to 24.4% for 2023, despite clear warnings from industry that the approach is unsustainable and jeopardizes the delivery of the government's ambitions for life sciences in the post-Brexit UK.

Europe United Kingdom

Capacity Challenges Prompt NICE To Consider Secondees From Consultancy Firms

England’s health technology assessment institute is exploring solutions to help deal with its increased workload, high staff turnover and challenges in recruiting people with the expertise needed.

Europe United Kingdom

UK Industry Attacks Government’s ‘Unsustainable’ Repayment Proposals

Questions are being raised about the credibility of the UK’s voluntary and statutory drug pricing schemes because of uncertainty over the payment percentages companies will have to pay in future.

Europe United Kingdom

2021: A Record-Breaking Year For ‘Smart’ Pricing And Access Deals In England

NHS England and Improvement (NHSE&I) agreed 16 pricing and access deals with drug companies in 2021, ten of which can be considered ‘smart.’ The fact that these were achieved against a backdrop of COVID-19 is seen as impressive.

United Kingdom Market Access
See All
UsernamePublicRestriction

Register